Skip to main content
Clinical Trials/IRCT20200415047080N1
IRCT20200415047080N1
Recruiting
Phase 3

A prospective randomized controlled trial to compare recombinant tissue-type plasminogen activator (rt-PA) and standard treatmentin in patients with ARDS induced by COVID-19

Tehran University of Medical Sciences0 sites30 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
COVID-19.
Sponsor
Tehran University of Medical Sciences
Enrollment
30
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • A person with laboratory confirmation of COVID\-19 infection
  • clinical and radiological confirmation of ARDS
  • The confirm case of covid\-19 in patients with ARDS (PaO2/FiO2a \= 300 or sat o2\= 315 mmHg (with PEEP or CPAP \= 5 cmH2O, or non\-ventilated)

Exclusion Criteria

  • Bleeding tendency
  • Coagulopathy (INR\>1\.5\)
  • Thrombocytopenia (plt\< 50000\)
  • Previous hypersensitivity to Alteplase
  • Active internal bleeding
  • Severe uncontrolled hypertension
  • Severe renal disease (GFR\<50 ml/min)
  • History of recent stroke
  • Hemoptysis at admission
  • Presence of any active malignancy (other than non\-melanoma skin cancer) that required treatment within the last 2 years

Outcomes

Primary Outcomes

Not specified

Similar Trials